about
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapEffectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host diseaseVDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia.Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells.Antibody-Based Treatment of Acute Myeloid Leukemia.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency.Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity.Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.Guidelines for an integrated diagnostic approach of chronic lymphoproliferative disorders in the routine laboratory of haematology in Belgium.Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
P2860
Q31033615-E88C2568-4565-4900-9947-853BBA704207Q33492227-AA7A4BA1-2AB6-4A15-8F0E-F6347FE394A7Q34433926-5909E7A9-8B65-4A77-8828-911B462E27F3Q35930604-EFBE2921-3643-4FED-88A1-9A0A74ECF621Q37211985-93855717-D987-4BD9-BAB4-2E213B073A26Q37377923-1CA181D5-01F0-4048-B3E3-4DD6E6884ED8Q38979277-8AB03EF0-28A0-43BF-9124-10B4D108A950Q39718346-FEAA151A-ED08-42A0-85FC-5CC81B8FE0D4Q41791356-7D37508F-638C-4DFF-92D1-6D7D5CDDE551Q41966008-925407BF-A796-4192-847D-87E6EF34A50FQ42836936-01495C42-E9DE-4010-B7C1-201A8F232505Q44100215-64C3438B-FD98-40CC-B421-4546F0FC4EBDQ45912894-22B7CC85-4969-460F-9AFB-C91B55CEC109Q45916399-DF315B50-93C1-4AD7-A940-688F8FF1F5AF
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Antibody therapy for chronic lymphocytic leukemia.
@ast
Antibody therapy for chronic lymphocytic leukemia.
@en
Antibody therapy for chronic lymphocytic leukemia.
@nl
type
label
Antibody therapy for chronic lymphocytic leukemia.
@ast
Antibody therapy for chronic lymphocytic leukemia.
@en
Antibody therapy for chronic lymphocytic leukemia.
@nl
prefLabel
Antibody therapy for chronic lymphocytic leukemia.
@ast
Antibody therapy for chronic lymphocytic leukemia.
@en
Antibody therapy for chronic lymphocytic leukemia.
@nl
P2860
P921
P1476
Antibody therapy for chronic lymphocytic leukemia.
@en
P2093
Beth A Christian
Thomas S Lin
P2860
P304
P356
10.1053/J.SEMINHEMATOL.2008.02.001
P577
2008-04-01T00:00:00Z